Docetaxel and Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases That Progressed on the Docetaxel and Placebo Group of MDA-ID-030008
Completed · Phase 2
Conditions studied: Metastatic Cancer, Prostate Cancer
In brief
RATIONALE: Drugs used in chemotherapy such as docetaxel work in different ways to stop tumor cells from dividing so they stop growing or die. Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Giving docetaxel with imatinib mesylate may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving docetaxel with imatinib mesylate works in treating patients with androgen-independent prostate cancer and bone metastases that progressed while receiving docetaxel and a placebo on clinical trial MDA-ID-030008.
Key facts
- Study ID
- NCT00084825
- Run by
- M.D. Anderson Cancer Center
- People needed
- 23
- Starts
- 2003-05-01
- Expected to finish
- 2008-06-01
- Last updated by the study team
- 2012-10-26
Who can join
Age: any. Sex: male. Healthy volunteers: not accepted.
Where it is running
- Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute — Boston, Massachusetts, United States
- Memorial Sloan-Kettering Cancer Center — New York, New York, United States
- M.D. Anderson Cancer Center at University of Texas — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.